Target intelligence / Profile preview

Immunoglobulin kappa variable 1-39 (IGKV1-39)

Target
IGKV1-39
Molecular classification
Other (Immunoglobulin variable domain, Antibody light chain variable region)
01

Overview

Immunoglobulin kappa variable 1-39 (IGKV1-39) encodes the V (variable) region of the kappa light chain in immunoglobulins (antibodies)[5][10][3]. This region forms part of the antigen binding site and contributes molecular diversity through V(D)J recombination and somatic hypermutation, which are essential for adaptive immune response and specificity[5][10][3]. The variable region of the kappa light chain, paired with the variable region of the heavy chain, determines the specificity of antibody–antigen interactions. The IGKV1-39 gene is present in the genome but does not produce a functional protein by itself; rather, it contributes to antibody diversity in B-cells via genetic rearrangement mechanisms[2][5]. Various alternative names reflect historical isolates of immunoglobulin light chains with IGKV1-39 sequence characteristics, often associated with certain monoclonal gammopathies or as research reagents[2][5][9]. IGKV1-39 is not a druggable therapeutic target, enzyme, transporter, or receptor, but is a critical genetic component of antibody variable regions and crucial for humoral immunity[7][10][8].

Other names
Ig kappa chain V-I region DEEIg kappa chain V-I region HauIg kappa chain V-I region MevIg kappa chain V-I region OUIg kappa chain V-I region WalkerIGKV139O12O12aIGKV1-39KV139
02

Biological functions

Antigen bindingImmune response
03

Disease associations

Other (monoclonal gammopathies, e.g., Bence-Jones proteins associated with some myelomas and amyloidosis)

Beyond the preview

Go deeper on Immunoglobulin kappa variable 1-39 (IGKV1-39).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin kappa variable 1-39 (IGKV1-39).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call